Tradjenta (linagliptin; Boehringer Ingelheim and Lilly) reduced blood sugar in adults with type 2 diabetes at risk for renal impairment, with a renal safety profile similar to that seen in other trials, according to findings from the MARLINA-T2D study.
Tradjenta is indicated as adjunct to diet and exercise in type 2 diabetes mellitus, as monotherapy or combination therapy. It is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases the concentrations of active incretin hormones, stimulating the release of insulin in a glucose-dependent manner and decreasing the levels of glucagon in the circulation.
The MARLINA-T2D study (n=360) evaluated the safety and efficacy of Tradjenta vs. placebo in patients with type 2 diabetes and albuminuria, defined as urinary albumin-to-creatinine ratio (UACR) 30–3000mg/g creatinine. At Week 24, Tradjenta was associated with a significant 0.6% reduction in A1C vs. placebo. The change in albuminuria was non-significant with Tradjenta when compared with placebo. Treatment with Tradjenta was well tolerated and a renal safety profile proved consistent with that of previous trials.
Findings from this study further support the use of Tradjenta as a once-daily treatment that does not require dose adjustment despite renal function, the study authors concluded.
It is available as 5mg strength tablets in 30- and 90-count bottles.
For more information call (800) 542-6257 or visit Tradjenta.com.